deltatrials
Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT02420977

Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

Evaluation of PSMA-based PET as an Imaging Biomarker of Androgen Receptor Signaling in High-Risk Localized and Locally Advanced Prostate Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Advanced Prostate Cancer
Interventions Pelvic DCFPyL PET-MRI fusion or PET/MRI
Updated 19 times since 2017 Last updated: Mar 18, 2025 Started: Dec 6, 2018 Primary completion: Mar 1, 2024 Completion: Mar 1, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Advanced Prostate Cancer, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 19 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~Apr 2019 · 4 months · monthly snapshot~Apr 2019 – ~Apr 2020 · 12 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jan 2022 · 9 months · monthly snapshot~Jan 2022 – ~Apr 2022 · 3 months · monthly snapshot~Apr 2022 – ~Nov 2022 · 7 months · monthly snapshot~Nov 2022 – ~Jul 2023 · 8 months · monthly snapshot~Jul 2023 – ~Mar 2024 · 8 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Apr 2025 · 4 months · monthly snapshot~Apr 2025 – present · 15 months · monthly snapshot

Change History

19 versions recorded

  1. Apr 2025 — Present [monthly]

    Completed EARLY_PHASE1

    Status: Active Not Recruiting → Completed

  2. Dec 2024 — Apr 2025 [monthly]

    Active Not Recruiting EARLY_PHASE1

  3. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting EARLY_PHASE1

  4. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting EARLY_PHASE1

  5. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting EARLY_PHASE1

▶ Show 14 earlier versions

  1. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting EARLY_PHASE1

  2. Jul 2023 — Mar 2024 [monthly]

    Active Not Recruiting EARLY_PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Nov 2022 — Jul 2023 [monthly]

    Recruiting EARLY_PHASE1

  4. Apr 2022 — Nov 2022 [monthly]

    Recruiting EARLY_PHASE1

  5. Jan 2022 — Apr 2022 [monthly]

    Recruiting EARLY_PHASE1

  6. Apr 2021 — Jan 2022 [monthly]

    Recruiting EARLY_PHASE1

  7. Jan 2021 — Apr 2021 [monthly]

    Recruiting EARLY_PHASE1

  8. Apr 2020 — Jan 2021 [monthly]

    Recruiting EARLY_PHASE1

  9. Apr 2019 — Apr 2020 [monthly]

    Recruiting EARLY_PHASE1

    Status: Not Yet Recruiting → Recruiting

  10. Dec 2018 — Apr 2019 [monthly]

    Not Yet Recruiting EARLY_PHASE1

  11. Jun 2018 — Dec 2018 [monthly]

    Not Yet Recruiting EARLY_PHASE1

  12. Feb 2018 — Jun 2018 [monthly]

    Not Yet Recruiting EARLY_PHASE1

    Phase: NA → EARLY_PHASE1

  13. Feb 2017 — Feb 2018 [monthly]

    Not Yet Recruiting NA

  14. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Data source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations